Get Premium to unlock powerful stock data
Acer Therapeutics Inc logo

Acer Therapeutics Inc

$ 2.19 +0.06 (+2.82%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 33.53M
Enterprise V:
$ 26.06M
Volume:
60.27K
Avg Vol (2M):
639.92K
Also Trade In:
Volume:
60.27K
Market Cap $:
33.53M
PE Ratio:
At Loss
Avg Vol (2-Month):
639.92K
Enterprise Value $:
26.06M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Acer Therapeutics Inc
NAICS : 325414 SIC : 2836
300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458
Description
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
Name Current Vs Industry Vs History
Cash-To-Debt 32.34
Equity-to-Asset -0.05
Debt-to-Equity -0.23
Debt-to-EBITDA -0.03
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.29
Distress
Grey
Safe
Beneish M-Score -5.67
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 24
3-Year EPS without NRI Growth Rate 24.3
3-Year FCF Growth Rate 81.2
Name Current Vs Industry Vs History
5-Day RSI 72.92
9-Day RSI 59.02
14-Day RSI 52.23
6-1 Month Momentum % -2.14
12-1 Month Momentum % -20.76

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.96
Quick Ratio 0.96
Cash Ratio 0.44
Days Sales Outstanding 2172.62

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.4
Name Current Vs Industry Vs History
Operating Margin % -1265.79
Net Margin % -1220.16
ROE % -286.28
ROA % -45.78
ROIC % -51.81
ROC (Joel Greenblatt) % -13493.23
ROCE % -221.32

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 24.61
EV-to-EBIT -1.63
EV-to-EBITDA -1.64
EV-to-Forward-EBITDA -1.18
EV-to-Revenue 20.68
EV-to-Forward-Revenue 2.46
EV-to-FCF -137.87
Earnings Yield (Greenblatt) % -61.35

Financials (Next Earnings Date:2022-08-10 Est.)

ACER's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ACER

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1.26
EPS (TTM) ($) -1.08
Beta 0.63
Volatility % 38.21
14-Day RSI 52.23
14-Day ATR ($) 0.167753
20-Day SMA ($) 2.0585
12-1 Month Momentum % -20.76
52-Week Range ($) 1.68 - 3.77
Shares Outstanding (Mil) 15.31

Piotroski F-Score Details

Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Acer Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More